Capricor Therapeutics, Inc.
CAPRHealthcareNASDAQBiotechnology · Last scanned Jun 13, 2026
Scan Results
Daily timeframePart of the healthcare sector, Capricor Therapeutics, Inc. (CAPR) is listed under Biotechnology. The company carries a $1.49B market cap, placing it firmly in the small-cap category. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Market Cap
$1.49B
Beta
0.37
P/E (TTM)
—
P/E (Fwd)
-33.78
EPS (TTM)
$-2.32
EPS (Fwd)
$-0.76
ROE
-56.4%
ROA
-31.2%
Cash
$278.6M
Total Debt
$14.8M
Free CF
-$70.5M
52W Change
108.4%
Annual Financials
Cash vs Debt
Capricor Therapeutics, Inc. holds $278.6M in cash against $14.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$70.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -56.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $2.6M (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of 0.37 suggests CAPR is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CAPR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.